Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramy Ibrahim

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
American Journal of Clinical Oncology|June 1, 2014
Do Sociodemographic Factors Influence Outcome in Prostate Cancer Patients Treated With External Beam Radiation Therapy?Avielle Movsas, Ramy Ibrahim, Mohamed A Elshaikh, et al.
Journal of Translational Medicine|January 30, 2010
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinomaOsama E Rahma, Ed Ashtar, Ramy Ibrahim, et al.
Cancer Immunology, Immunotherapy : CII|December 20, 2018
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, ItalyMichele Maio, George Coukos, Soldano Ferrone, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
The Journal of Experimental Medicine|August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancerApostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
American Journal of Clinical Oncology|June 1, 2014
Do Sociodemographic Factors Influence Outcome in Prostate Cancer Patients Treated With External Beam Radiation Therapy?Avielle Movsas, Ramy Ibrahim, Mohamed A Elshaikh, et al.
Journal of Translational Medicine|January 30, 2010
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinomaOsama E Rahma, Ed Ashtar, Ramy Ibrahim, et al.
Cancer Immunology, Immunotherapy : CII|December 20, 2018
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, ItalyMichele Maio, George Coukos, Soldano Ferrone, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
The Journal of Experimental Medicine|August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancerApostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Pageof 5